Group 1 - Neurocrine Biosciences has scheduled its Q2 2025 financial results conference call and webcast for July 30, 2025, at 1:30 p.m. PT [1][4] - The conference call will be accessible via the company's website, and a replay will be available approximately one hour after the event [1][4] - The company focuses on developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders, with a diverse portfolio of FDA-approved treatments [2] Group 2 - Neurocrine's portfolio includes treatments for tardive dyskinesia, Huntington's disease-related chorea, congenital adrenal hyperplasia, endometriosis, and uterine fibroids, with some collaborations [2] - The company has a robust pipeline with multiple compounds in mid- to late-phase clinical development across its core therapeutic areas [2]

Core Insights - Neurocrine Biosciences, Inc. will participate in two investor conferences in May 2025, showcasing its commitment to engaging with investors and stakeholders [1][5]. Company Overview - Neurocrine Biosciences is a leading biopharmaceutical company focused on neuroscience, dedicated to developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders [3]. - The company has a diverse portfolio that includes FDA-approved treatments for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis, and uterine fibroids, along with a robust pipeline of compounds in mid- to late-phase clinical development [3]. Upcoming Events - CEO Kyle Gano and VP of Investor Relations Todd Tushla will present at the BofA Securities 2025 Health Care Conference on May 13, 2025, at 11:20 AM Pacific Time in Las Vegas [5]. - CFO Matt Abernethy and CCO Eric Benevich will present at the RBCCM Global Healthcare Conference on May 20, 2025, at 11:30 AM Eastern Time in New York [5].